Literature DB >> 26817955

Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease.

Erica M Sparkenbaugh1, Pichika Chantrathammachart2, Kasemsiri Chandarajoti3, Nigel Mackman4, Nigel S Key4, Rafal Pawlinski4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26817955      PMCID： PMC4786843          DOI： 10.1182/blood-2015-11-681114

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  24 in total

Review 1.  Sickle-cell disease and the heart: review of the current literature.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Evangelos Terpos
Journal:  Br J Haematol       Date:  2012-04-25       Impact factor: 6.998

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 3.  The role of interleukin-6 in the failing heart.

Authors:  K C Wollert; H Drexler
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

4.  Tissue factor expression by endothelial cells in sickle cell anemia.

Authors:  A Solovey; L Gui; N S Key; R P Hebbel
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

5.  EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Irene Hernandez; Sreemanti Basu; Mark Zogg; Fady Botros; Shuang Jia; Martin J Hessner; John H Griffin; Wolfram Ruf; Hartmut Weiler
Journal:  Blood       Date:  2015-03-02       Impact factor: 22.113

6.  Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes.

Authors:  M Sano; K Fukuda; H Kodama; J Pan; M Saito; J Matsuzaki; T Takahashi; S Makino; T Kato; S Ogawa
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

7.  Low levels of tissue factor are compatible with development and hemostasis in mice.

Authors:  G C Parry; J H Erlich; P Carmeliet; T Luther; N Mackman
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

8.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

9.  Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.

Authors:  Arun S Shet; Omer Aras; Kalpna Gupta; Mathew J Hass; Douglas J Rausch; Nabil Saba; Louann Koopmeiners; Nigel S Key; Robert P Hebbel
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

10.  Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.

Authors:  Barbara Coles; Ceri A Fielding; Stefan Rose-John; Jürgen Scheller; Simon A Jones; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307
View more
  7 in total

Review 1.  Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors:  Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

2.  Role of the coagulation system in the pathogenesis of sickle cell disease.

Authors:  Md Nasimuzzaman; Punam Malik
Journal:  Blood Adv       Date:  2019-10-22

3.  High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Malgorzata Kasztan; Michael W Henderson; Patrick Ellsworth; Parker Ross Davis; Kathryn J Wilson; Brandi Reeves; Nigel S Key; Sidney Strickland; Keith McCrae; David M Pollock; Rafal Pawlinski
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

4.  Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

Authors:  Camille Faes; Anton Ilich; Amandine Sotiaux; Erica M Sparkenbaugh; Michael W Henderson; Laura Buczek; Joan D Beckman; Patrick Ellsworth; Denis F Noubouossie; Lantarima Bhoopat; Mark Piegore; Céline Renoux; Wolfgang Bergmeier; Yara Park; Kenneth I Ataga; Brian Cooley; Alisa S Wolberg; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2019-04-05       Impact factor: 22.113

5.  A coagulation defect arising from heterozygous premature termination of tissue factor.

Authors:  Sol Schulman; Emale El-Darzi; Mary Hc Florido; Max Friesen; Glenn Merrill-Skoloff; Marisa A Brake; Calvin R Schuster; Lin Lin; Randal J Westrick; Chad A Cowan; Robert Flaumenhaft; Willem H Ouwehand; Kathelijne Peerlinck; Kathleen Freson; Ernest Turro; Bruce Furie
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

6.  Venous Thromboembolism in Sickle Cell Disease is Associated with Neutrophilia.

Authors:  Jahnavi Gollamudi; Shashank Sarvepalli; Animesh Vadaparti Binf; Tara Alin; Jane A Little; Lalitha Nayak
Journal:  Hemoglobin       Date:  2021-02-15       Impact factor: 0.849

Review 7.  Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.

Authors:  Maria A Lizarralde-Iragorri; Arun S Shet
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.